1. Home
  2. XXI vs HROW Comparison

XXI vs HROW Comparison

Compare XXI & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twenty One Capital Inc. Class A Common Stock

XXI

Twenty One Capital Inc. Class A Common Stock

N/A

Current Price

$4.95

Market Cap

1.8B

Sector

Finance

ML Signal

N/A

HROW

Harrow Inc.

HOLD

Current Price

$39.48

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XXI
HROW
Founded
2025
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2026
2008

Fundamental Metrics

Financial Performance
Metric
XXI
HROW
Price
$4.95
$39.48
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$69.86
AVG Volume (30 Days)
1.8M
550.4K
Earning Date
06-12-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
71.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$31.62
Revenue Next Year
N/A
$50.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.15
$28.54
52 Week High
$11.49
$54.98

Technical Indicators

Market Signals
Indicator
XXI
HROW
Relative Strength Index (RSI) 51.52 49.09
Support Level $4.15 $37.03
Resistance Level $5.71 $41.82
Average True Range (ATR) 0.24 1.80
MACD 0.10 -0.00
Stochastic Oscillator 87.36 49.15

Price Performance

Historical Comparison
XXI
HROW

About XXI Twenty One Capital Inc. Class A Common Stock

Twenty One Capital Inc is engaged in the Bitcoin-related business lines. It engages in two principal activities: actively accumulating Bitcoin and managing its Bitcoin holdings, and commencing development of educational materials and branded content intended to drive increased institutional and retail investor Bitcoin literacy.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: